Role of Litigation in Defining Drug Risks_JAMA / BMJ

Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.Below are excerpts from two timely articles that offer persuasive arguments backed by evidence demonstrating that litigation provides vital drug safety information that physicians and the public need to protect consumers from drug-induced hazards. Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.

The Role of Litigation in Defining Drug Risks by Drs. Aaron Kesselheim and Jerry Avorn is in the current issue of the Journal of the American Medical Association (JAMA). [1] What have we learnt from Vioxx? by Drs. Harlan Krumholz, David Egilman and colleagues appears in the current BMJ. [2] 

1. The authors of the JAMA article examined some 9 case examples finding that: “there are often important gaps in the ascertainment and reporting of adverse effects associated with prescription drugs” that the surveillance system simply does not address.
The case examples: Valdecoxib (Bextra); Olanzapine (Zyprexa); Paroxetine (Paxil); Cerivastatin (Baycol); Trogitazone (Rezulin): Rofecoxib (Vioxx); Defenfluramine (Redux); Cisapride (Propulsid).  Read More….

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: